Analysts from Robert W. Baird and Roth Capital explain why they are bullish on rival drug-maker Sarepta Therapeutics Inc (NASDAQ:SRPT) and biopharmaceutical firm Celator Pharmaceuticals …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee of …
Analysts are weighing in on biotechnology firms Peregrine Pharmaceuticals (NASDAQ:PPHM), Sarepta Therapeutics Inc (NASDAQ:SRPT), and Cara Therapeutics Inc (NASDAQ:CARA). Here’s a quick roundup of today’s …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months and year ended December 31, 2015, …
Oppenheimer analysts express mixed sentiments on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) as one company awaits an extended review from the FDA …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S.
Yesterday was a great day for biotech stocks. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which tracks 144 biotech and pharmaceutical companies, reversed losses and surged …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, announced that the U.S.
The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index (IBB) is down 19% so far in 2016, …
The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which tracks 144 biotech and pharmaceutical companies – fell nearly 4% this week amid a renewed selloff in …
